Mere Way
Nottingham
NG11 6JS
United Kingdom
+44 115 974 9000
Quotient Sciences is a drug development and manufacturing accelerator providing integrated services across the entire development pathway for small molecules & peptide drug programs. We cut through silos across a range of drug development capabilities, saving precious time and money in getting drugs to patients. With drug development and clinical testing facilities located in both the US and the UK, we work with customers in a flexible way by either designing and delivering fully integrated programs at each stage of the development lifecycle, or by providing them support through tailored individual services in Drug Substance Synthesis & Manufacturing, Formulation Development, Clinical Trial Manufacturing, Commercial Manufacturing, Clinical Pharmacology, Data Sciences, Bioanalysis and Drug Development Consulting. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solution
Quotient Sciences has over 30 years of experience developing and manufacturing a breadth of formulations across a range of indications and across an array of drug product formats including oral, inhaled, parenteral & topical. We also have a depth of expertise in process research & development (PR&D), continuous flow, modified release, oral peptides, ADME studies, Radiolabeling, scintigraphy, pediatrics and we have the ability to handle highly potent compounds. Our innovative approach to formulation development is based on our proven track record in early clinical evaluation delivering phase-appropriate formulations across the product development pathway from candidate selection thru commercial product launch. Our global locations include Nottingham, UK, Reading, UK, Alnwick, UK, Edinburgh, UK, Philadelphia, PA, USA and Miami, FL, USA.
We take an agile and flexible approach with our customers programs, offering bespoke drug substance synthesis and manufacturing, helping to accelerate molecules from candidate selection to clinical proof-of-concept and onwards towards commercial scale. Our 40+ years of expertise in a wide range of synthetic organic chemistry coupled with extensive experience in flow chemistry, synthetic biology and biocatalysis can significantly save months of development time for our customers.
Translational Pharmaceutics® is our unique, flagship platform which accelerates drug development by integrating drug substance, formulation development, real-time manufacturing, and clinical testing. The platform has been proven to save >12 months of development time and reduce R&D costs up to $100M, it’s been used by global pharmaceutical and biotech companies on over 500 drug programs in the past 15 years.
Download the white paper 'Assessing the Financial Impact of Translational Pharmaceutics'
Quotient Sciences has almost 30 years of experience developing a breadth of pharmaceutical formulations across a range of indications. Our innovative approach to formulation development integrates drug product development with clinical evaluation, combined with our experience with over 1,500 molecules at all stages of drug development.
Understanding that early phase clinical testing is a pivotal milestone in the development of your drug product, Quotient offers a clinical trial manufacturing, testing and certification service designed to meet your individual requirements. Our innovative method of building integrated GMP and GCP programs provides you with a streamlined, flexible approach to drug product supply that reflects your clinical study design and timeline. We understand the time and cost pressures you face during early phase evaluation and work with you to ensure a rapid, seamless path from development to clinical trial supply.
When you are looking for a partner who is dedicated to Phase I trials and early clinical development, rely on Quotient Sciences for the experience and expertise to seamlessly deliver your studies with the highest quality service and speed. We accelerate your molecule from first-in-human to proof-of-concept, helping you make critical decisions earlier and faster. Whatever Phase I clinical pharmacology study you require, you can expect a fully integrated program from study design and start-up to data reporting.
Quotient Sciences is a global player in commercial drug product manufacture of small molecule products for niche therapies including oncology and orphan drugs. Our commercial manufacturing facility located in Philadelphia is designed to handle your high-potency compounds.
You need data rapidly to make crucial decisions during a study. Faster data means we can provide our customers with earlier interim data and interim PK reports for on-study dosing and formulation decisions. We understand on-study changes to early phase study designs and dosing are frequent and so our study strategy for study database design and reporting is built around flexibility and rapid implementation. We use eSource data collection procedures in our clinical units and a joint eSource/eCRF database. Data are available in the study database within hours of collection, ready for remote sponsor access.
Our Drug Development Consultants work with you to design and implement successful drug development programs. With industry leading scientific expertise across a range of technical disciplines, we help customers across all stages of development, from candidate selection to commercial launch. Our consultants have a proven track-record of cutting across industry silos to reduce the time and cost of development. With hands-on development experience across hundreds of drug molecules and product types, we’ll help you avoid critical pitfalls, manage risks and maximise the potential for success.
